FINWIRES · TerminalLIVE
FINWIRES

Celltrion Files Phase 3 Trial Amendment for CT-P44 Biosimilar for Myeloma

By

Celltrion (KRX:068270) said it submitted an amendment to the Phase 3 clinical trial protocol for CT-P44, a biosimilar candidate for Darzalex, to South Korea's Ministry of Food and Drug Safety.

The trials will evaluate the efficacy and safety of CT-P44 against Darzalex Faspro in patients with relapsed or refractory multiple myeloma, according to a Tuesday filing with the Korea Exchange.

The amendment is filed to adjust the number of trial participants following a change in its regulatory strategy, and the randomized, double-blind trial is expected to involve 394 participants and run for two years.

Related Articles

Asia

Hubei Dinglong to Allot 1 Billion Yuan for Wealth Management Products; Shares Jump 9%

Hubei Dinglong (SHE:300054) will allocate up to 1 billion yuan for the purchase of wealth management products using its idle funds, according to a Tuesday disclosure to the Shenzhen bourse.The wealth management products will help with the efficient use of capital, it said in the filing.Shares rose 9% during the midday break on Tuesday.

SHE:300054
Asia

Inspace Creation Bags Malaysia Distribution Rights to Novah Furniture Products

Inspace Creation (KLSE:INSPACE), through its subsidiary Image Articulation, has entered into a distribution agreement with office furniture company Novah, according to a Monday filing with Bursa Malaysia.Under the pact, Image Articulation will be the exclusive distributor of certain Novah-branded office furniture products within Malaysia.The agreement is initially for two years starting Aug. 1, and will be automatically renewed for an additional two years if Image Articulation achieves at least 80% of the applicable sales targets.

KLSE:INSPACE
Asia

Hanwha Aerospace Ends KRW455 Billion Supply Contract with UK's Vertical Aerospace

Hanwha Aerospace (KRX:012450) said it terminated a 454.8 billion won contract with U.K.-based Vertical Aerospace, according to a Tuesday filing with the Korea Exchange.The contract, signed in August 2022, involved the development and supply of electromechanical actuators, tilting systems and blade pitch systems for Vertical Aerospace's VX4 aircraft.The South Korean aerospace company said the decision was made by mutual agreement following changes in market conditions and business direction relative to the project's original objectives.Hanwha said the companies simultaneously signed a memorandum of understanding to maintain their cooperative relationship and lay the groundwork for future collaboration on similar projects.Shares of Hanwha Aerospace jumped over 10% in recent trade.

KRX:012450